Distal myopathy

Last updated
Distal myopathy
Other namesDistal muscular dystrophy
Body Diagram.png
Red depicts the preferentially affected areas in distal myopathy.
Specialty Neurology, neuromuscular medicine
Symptoms Weakness of hands and/or feet
Complications Cardiomyopathy
Usual onsetVariable
DurationLifetime
TypesClassic, myofibrillar myopathy, other
CausesGenetic mutation of various genes
Diagnostic method Genetic testing, muscle biopsy
FrequencyRare

Distal myopathy is a group of rare genetic disorders that cause muscle damage and weakness, predominantly in the hands and/or feet. Mutation of many different genes can be causative. Many types involve dysferlin. [1]

Contents

Signs and symptoms

All of the different types affect different regions of the extremities and can show up as early as 5 years of age to as late as 50 years old. Distal myopathy has slow progress therefore the patient may not know that they have it until they are in their late 40s or 50s.[ citation needed ]

Miyoshi myopathy affects the posterior muscles of the lower leg, more so than the anterior muscles of the lower leg. [2] [3]

Cause

DYSF 4ihb pdb.png
DYSF

The cause of this myopathy is very hard to determine because it can be a mutation in any of at least eight genes and not all are known yet. These mutations can be inherited from one parent, autosomal dominant, or from both parents, autosomal recessive. There are eight known types of distal myopathy.[ citation needed ]

Types

Classic distal muscular dystrophies
TypeEponymInheritance OMIM GeneLocusGene also implicated in:
Late adult-onset type 1 [4] WelanderAD [5] 604454 TIA1 [6] 2p13 [7]
Late adult-onset type 2a [5] - Finnish (tibial)UddAD [5] 600334 TTN [5] 2q31.2
Late adult-onset type 2b [5] Markesbery–GriggsAD [8] ZASP [5] 10q23.2
Early adult-onset type 1 [4] NonakaAR [5] 605820 GNE [5] 9p13.3
Early adult-onset type 2 [4] MiyoshiAR [5] 254130 DYSF [5] 2p13.3-p13.1 limb-girdle muscular dystrophy type 2B. [9]
Distal myopathy with anterior tibial onset (DMAT) [10] [11] 606768 DMAT can be considered a variant of Miyoshi.
Early adult-onset type 3 [4] Laing (Gower)AD [5] 160500 MYH7 [5] 14q11.2
AD = autosomal dominant; AR = autosomal recessive
Myofibrillar myopathies classifiable as distal myopathy
TypeEponymInheritance OMIM GeneLocusGene also implicated in:
Desmin — adult onset (MFM1) [5]

Hereditary inclusion-body myositis type 1 [5]

AD
αB-crystallin — early - mid adult (MFM2) [5] AD
ZASP— late adult (MFM4) [5] AD
Scapuloperoneal [5] AD
MFM = myofibrillary myopathy; AD = autosomal dominant; AR = autosomal recessive
Other distal muscular dystrophies
TypeEponymInheritance OMIM GeneLocusGene also implicated in:
Distal myopathy with vocal cord and pharyngeal weakness [4] AD [5] 606070 MATR3 [5] 5q31 [5] Amyotrophic lateral sclerosis 21 (ALS21). One study suggests that all cases are ALS, justifying reclassification. [12]

Diagnosis

In terms of diagnosis, Vocal cord and pharyngeal distal myopathy should be assessed via serum CK levels, as well as muscle biopsy of the individual suspected of being afflicted with this condition [13]

Management

As of 2011, no disease modifying treatments are known. [8] Foot drop can be managed with ankle-foot orthoses or surgical tendon transfer, [8] in which the tibialis posterior muscle is repurposed to function as a tibialis anterior muscle. In select types of distal myopathy, evaluation of the heart may be indicated. [8] Scoliosis and contractures can be surgically managed. [8] In 2024 a drug to treat distal myopathy was approved in Japan. [14]

Related Research Articles

<span class="mw-page-title-main">Muscular dystrophy</span> Genetic disorder

Muscular dystrophies (MD) are a genetically and clinically heterogeneous group of rare neuromuscular diseases that cause progressive weakness and breakdown of skeletal muscles over time. The disorders differ as to which muscles are primarily affected, the degree of weakness, how fast they worsen, and when symptoms begin. Some types are also associated with problems in other organs.

<span class="mw-page-title-main">Limb–girdle muscular dystrophy</span> Medical condition

Limb–girdle muscular dystrophy (LGMD) is a genetically heterogeneous group of rare muscular dystrophies that share a set of clinical characteristics. It is characterised by progressive muscle wasting which affects predominantly hip and shoulder muscles. LGMD usually has an autosomal pattern of inheritance. It currently has no known cure or treatment.

Myotonia is a symptom of a small handful of certain neuromuscular disorders characterized by delayed relaxation of the skeletal muscles after voluntary contraction or electrical stimulation, and the muscle shows an abnormal EMG.

<span class="mw-page-title-main">Spinal muscular atrophies</span> Group of disorders

Spinal muscular atrophies (SMAs) are a genetically and clinically heterogeneous group of rare debilitating disorders characterised by the degeneration of lower motor neurons and subsequent atrophy (wasting) of various muscle groups in the body. While some SMAs lead to early infant death, other diseases of this group permit normal adult life with only mild weakness.

<span class="mw-page-title-main">Dystrophin</span> Rod-shaped cytoplasmic protein

Dystrophin is a rod-shaped cytoplasmic protein, and a vital part of a protein complex that connects the cytoskeleton of a muscle fiber to the surrounding extracellular matrix through the cell membrane. This complex is variously known as the costamere or the dystrophin-associated protein complex (DAPC). Many muscle proteins, such as α-dystrobrevin, syncoilin, synemin, sarcoglycan, dystroglycan, and sarcospan, colocalize with dystrophin at the costamere. It has a molecular weight of 427 kDa

<span class="mw-page-title-main">Titin</span> Largest-known protein in human muscles

Titin is a protein that in humans is encoded by the TTN gene. Titin is a protein, over 1 μm in length, that functions as a molecular spring that is responsible for the passive elasticity of muscle. It comprises 244 individually folded protein domains connected by unstructured peptide sequences. These domains unfold when the protein is stretched and refold when the tension is removed.

Nemaline myopathy is a congenital, often hereditary neuromuscular disorder with many symptoms that can occur such as muscle weakness, hypoventilation, swallowing dysfunction, and impaired speech ability. The severity of these symptoms varies and can change throughout one's life to some extent. The prevalence is estimated at 1 in 50,000 live births. It is the most common non-dystrophic myopathy.

<span class="mw-page-title-main">Facioscapulohumeral muscular dystrophy</span> Medical condition

Facioscapulohumeral muscular dystrophy (FSHD) is a type of muscular dystrophy, a group of heritable diseases that cause degeneration of muscle and progressive weakness. Per the name, FSHD tends to sequentially weaken the muscles of the face, those that position the scapula, and those overlying the humerus bone of the upper arm. These areas can be spared, and muscles of other areas usually are affected, especially those of the chest, abdomen, spine, and shin. Almost any skeletal muscle can be affected in advanced disease. Abnormally positioned, termed 'winged', scapulas are common, as is the inability to lift the foot, known as foot drop. The two sides of the body are often affected unequally. Weakness typically manifests at ages 15 – 30 years. FSHD can also cause hearing loss and blood vessel abnormalities at the back of the eye.

<span class="mw-page-title-main">Mitochondrial myopathy</span> Medical condition

Mitochondrial myopathies are types of myopathies associated with mitochondrial disease. Adenosine triphosphate (ATP), the chemical used to provide energy for the cell, cannot be produced sufficiently by oxidative phosphorylation when the mitochondrion is either damaged or missing necessary enzymes or transport proteins. With ATP production deficient in mitochondria, there is an over-reliance on anaerobic glycolysis which leads to lactic acidosis either at rest or exercise-induced.

<span class="mw-page-title-main">Dysferlin</span> Protein encoded by the DYSF gene in humans

Dysferlin also known as dystrophy-associated fer-1-like protein is a protein that in humans is encoded by the DYSF gene. Dysferlin is linked with plasma membrane repair., stabilization of calcium signaling and the development of the T-tubule system of the muscle A defect in the DYSF gene, located on chromosome 2p12-14, results in several types of muscular dystrophy; including Miyoshi myopathy (MM), Limb-girdle muscular dystrophy type 2B (LGMD2B) and Distal Myopathy (DM). A reduction or absence of dysferlin, termed dysferlinopathy, usually becomes apparent in the third or fourth decade of life and is characterised by weakness and wasting of various voluntary skeletal muscles. Pathogenic mutations leading to dysferlinopathy can occur throughout the DYSF gene.

<span class="mw-page-title-main">Zaspopathy</span> Medical condition

Zaspopathy, also called ZASP-related myofibril myopathy, is a novel autosomal dominant form of progressive muscular dystrophy, first described in 2005.

<span class="mw-page-title-main">Bethlem myopathy</span> Medical condition

Bethlem myopathy is predominantly an autosomal dominant myopathy, classified as a congenital form of limb-girdle muscular dystrophy. There are two types of Bethlem myopathy, based on which type of collagen is affected.

<span class="mw-page-title-main">MYOT</span> Mammalian protein found in Homo sapiens

Myotilin is a protein that in humans is encoded by the MYOT gene. Myotilin also known as TTID is a muscle protein that is found within the Z-disc of sarcomeres.

<span class="mw-page-title-main">Ullrich congenital muscular dystrophy</span> Medical condition

Ullrich congenital muscular dystrophy (UCMD) is a form of congenital muscular dystrophy. There are two forms: UCMD1 and UCMD2.

Collagen VI (ColVI) is a type of collagen primarily associated with the extracellular matrix of skeletal muscle. ColVI maintains regularity in muscle function and stabilizes the cell membrane. It is synthesized by a complex, multistep pathway that leads to the formation of a unique network of linked microfilaments located in the extracellular matrix (ECM). ColVI plays a vital role in numerous cell types, including chondrocytes, neurons, myocytes, fibroblasts, and cardiomyocytes. ColVI molecules are made up of three alpha chains: α1(VI), α2(VI), and α3(VI). It is encoded by 6 genes: COL6A1, COL6A2, COL6A3, COL6A4, COL6A5, and COL6A6. The chain lengths of α1(VI) and α2(VI) are about 1,000 amino acids. The chain length of α3(VI) is roughly a third larger than those of α1(VI) and α2(VI), and it consists of several spliced variants within the range of 2,500 to 3,100 amino acids.

<span class="mw-page-title-main">ANO5</span> Protein-coding gene in the species Homo sapiens

Anoctamin 5 (ANO5) is a protein that in humans is encoded by the ANO5 gene.

<span class="mw-page-title-main">Ferlins</span> Protein family

Ferlins are an ancient protein family involved in vesicle fusion and membrane trafficking. Ferlins are distinguished by their multiple tandem C2 domains, and sometimes a FerA and a DysF domain. Mutations in ferlins can cause human diseases such as muscular dystrophy and deafness. Abnormalities in expression of myoferlin, a human ferlin protein, is also directly associated with higher mortality rate and tumor recurrence in several types of cancer, including pancreatic, colorectal, breast, cervical, stomach, ovarian, cervical, thyroid, endometrial, and oropharyngeal squamous cell carcinoma. In other animals, ferlin mutations can cause infertility.

Lisa Welander was a Swedish neurologist, and was Sweden's first professor of neurology, taking up her professorship at Umeå University from 1964–75.

<span class="mw-page-title-main">Pseudoathletic appearance</span> Medical sign

Pseudoathletic appearance is a medical sign meaning to have the false appearance of a well-trained athlete due to pathologic causes instead of true athleticism. It is also referred to as a Herculean or bodybuilder-like appearance. It may be the result of muscle inflammation, muscle hyperplasia, muscle hypertrophy, muscle pseudohypertrophy, or symmetrical subcutaneous deposits of fat or other tissue.

References

  1. Murakami N, Sakuta R, Takahashi E, et al. (December 2005). "Early onset distal muscular dystrophy with normal dysferlin expression". Brain Dev. 27 (8): 589–91. doi:10.1016/j.braindev.2005.02.002. PMID   16310593. S2CID   28957231.
  2. Soares CN, de Freitas MR, Nascimento OJ, da Silva LF, de Freitas AR, Werneck LC (December 2003). "Myopathy of distal lower limbs: the clinical variant of Miyoshi". Arq Neuropsiquiatr. 61 (4): 946–9. doi: 10.1590/S0004-282X2003000600011 . PMID   14762596.
  3. Aoki, Masashi (1 January 1993). "Dysferlinopathy". GeneReviews. PMID   20301480 . Retrieved 10 May 2016.
  4. 1 2 3 4 5 Saperstein, DS; Amato, AA; Barohn, RJ (November 2001). "Clinical and genetic aspects of distal myopathies". Muscle & Nerve. 24 (11): 1440–50. doi:10.1002/mus.1167. PMID   11745945. S2CID   26573674.
  5. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Dimachkie, MM; Barohn, RJ (August 2014). "Distal myopathies". Neurologic Clinics. 32 (3): 817–42, x. doi:10.1016/j.ncl.2014.04.004. PMC   4109660 . PMID   25037092.
  6. Hackman P, Sarparanta J, Lehtinen S, Vihola A, Evilä A, Jonson PH, Luque H, Kere J, Screen M, Chinnery PF, Åhlberg G, Edsröm L, Udd B (January 2013). "Welander Distal Myopathy Is Caused by a Mutation in the RNA-Binding Protein TIA1". Annals of Neurology. 73 (4): 500–509. doi:10.1002/ana.23831. PMID   23401021. S2CID   13908127.
  7. von Tell D, Bruder CE, Anderson LV, Anvret M, Ahlberg G (August 2003). "Refined mapping of the Welander distal myopathy region on chromosome 2p13 positions the new candidate region telomeric of the DYSF locus". Neurogenetics. 4 (4): 173–7. doi:10.1007/s10048-003-0154-z. PMID   12836053. S2CID   27539044.
  8. 1 2 3 4 5 Udd, B (2011). Distal muscular dystrophies. Handbook of Clinical Neurology. Vol. 101. pp. 239–62. doi:10.1016/B978-0-08-045031-5.00016-5. ISBN   9780080450315. PMID   21496636.
  9. Illa I (March 2000). "Distal myopathies". J. Neurol. 247 (3): 169–74. doi:10.1007/s004150050557. PMID   10787109. S2CID   39723106. Archived from the original on 2013-02-13.
  10. Liu, J; Aoki, M; Illa, I; Wu, C; Fardeau, M; Angelini, C; Serrano, C; Urtizberea, JA; Hentati, F; Hamida, MB; Bohlega, S; Culper, EJ; Amato, AA; Bossie, K; Oeltjen, J; Bejaoui, K; McKenna-Yasek, D; Hosler, BA; Schurr, E; Arahata, K; de Jong, PJ; Brown RH, Jr (September 1998). "Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy". Nature Genetics. 20 (1): 31–6. doi:10.1038/1682. PMID   9731526. S2CID   12018395.
  11. Illa, I; Serrano-Munuera, C; Gallardo, E; Lasa, A; Rojas-García, R; Palmer, J; Gallano, P; Baiget, M; Matsuda, C; Brown, RH (January 2001). "Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype". Annals of Neurology. 49 (1): 130–4. doi:10.1002/1531-8249(200101)49:1<130::AID-ANA22>3.0.CO;2-0. PMID   11198284.
  12. Johnson, JO; Pioro, EP; Boehringer, A; Chia, R; Feit, H; Renton, AE; Pliner, HA; Abramzon, Y; Marangi, G; Winborn, BJ; Gibbs, JR; Nalls, MA; Morgan, S; Shoai, M; Hardy, J; Pittman, A; Orrell, RW; Malaspina, A; Sidle, KC; Fratta, P; Harms, MB; Baloh, RH; Pestronk, A; Weihl, CC; Rogaeva, E; Zinman, L; Drory, VE; Borghero, G; Mora, G; Calvo, A; Rothstein, JD; ITALSGEN.; Drepper, C; Sendtner, M; Singleton, AB; Taylor, JP; Cookson, MR; Restagno, G; Sabatelli, M; Bowser, R; Chiò, A; Traynor, BJ (May 2014). "Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis". Nature Neuroscience. 17 (5): 664–666. doi:10.1038/nn.3688. PMC   4000579 . PMID   24686783.
  13. Udd, Bjarne (1 January 2011). "Distal muscular dystrophies". Muscular Dystrophies. Handbook of Clinical Neurology. Vol. 101. pp. 239–262. doi:10.1016/B978-0-08-045031-5.00016-5. ISBN   9780080450315. ISSN   0072-9752. PMID   21496636.  via ScienceDirect  (Subscription may be required or content may be available in libraries.)
  14. "Persistence pays off with approval of distal myopathy drug". The Japan Times. 20 May 2024.

Further reading